

solo™

The preferred
first-line therapy
for glaucoma, SLT.

Designed specifically for selective laser trabeculoplasty (SLT), Solo allows you to perform quick and highly accurate glaucoma laser treatments customized to each individual patient's response.

LiGHT Trial¹ confirms SLT as preferred first-line therapy for glaucoma

The pivotal results of the multi-center LiGHT trial compared the use of SLT versus drops as a first-line treatment for treatment-naïve patients who had POAG or OHT over 36 months.



n = 652

**SLT (329 patients)
Eye drops (323 patients)**

>74.2%

**74.2% of SLT patients
reached target IOP,
drop-free**

1 Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Gus Gazzard, Evgenia Konstantakopoulou, David Garway-Heath, et al.; on behalf of the LiGHT Trial Study Group.



**LUMIBIRD
MEDICAL**

Glaucoma treatment



TECHNICAL SPECIFICATIONS

Laser Source	Q-switched, frequency doubled Nd:YAG
Wavelength	Green 532 nm
Energy	0.3 to 2.6 mJ, single pulse, continuously variable
Pulse Width	3 ns
Spot Size	400 µm
Repetition Rate	up to 3 Hz
Aiming Beam	Red 635 nm, adjustable intensity
Magnification	10x, 16x, 28x
Cooling	Air-cooled
Weight	30 kg, 66 lbs (laser only)
Dimensions (HxWxD)	57x75x44 cm, 23x30x18 in (laser only)



SLT from Ellex®

Custom-designed optics that provide an enhanced view of the trabecular meshwork

LED illumination for superior visualization and greater patient benefits

Ultra-stable laser energy output

Sharp edged SLT aiming beam for critical focus

Comprehensive energy tracking system, regulating settings for extended duration

Evaluate pathology

If SLT is effective, primary obstruction may reside within the trabecular meshwork

If SLT is ineffective, primary obstruction may reside distal to trabecular meshwork

Treat Glaucoma - naturally

Stimulate the eye's natural healing response

Eliminate the burn and scar tissue associated with ALT

Eliminate the issues of compliance and side effects associated with medications

Specifications are subject to change without notice. Non contractual pictures.
© 2026, Lumibird Medical. Ellex® and Solo™ are trademarks of Ellex Medical Pty Ltd,
member of Lumibird Medical Division. All rights reserved.
8448343EN-A_FLYER SOLO UKCA ENGLISH- XL_Solo_BC2_UK_251204



LASER CLASS 3B Nd:YAG: 532nm, 6mJ Max, 3ns pulse
LASER CLASS 2 Diode Laser: 635nm, <1mW Max CW

**WARNING - VISIBLE AND INVISIBLE LASER
RADIATION - AVOID EXPOSURE TO BEAM**

CLASS 3B LASER PRODUCT per IEC 60825-1:2014



Manufacturer

Ellex Medical Pty Ltd
3-4 Second Avenue
Mawson Lakes, SA 5095 Australia
Tel: +61 (0)8 7074 8200
ISO 13485 : 2016

Headquarters

Lumibird Medical
1, Rue du Bois Joli - CS40015
63808 Cournon d'Auvergne - France
Tel: +33 (0)4 73 745 745

ELLEX
A brand of



LUMIBIRD®
MEDICAL

www.lumibirdmedical.com